Long-term management of prolactinomas - Use of long-acting dopamine agonists

Reviews in Endocrine and Metabolic Disorders

Volumn 6, Issue 1, 2005, Pages 15-21

  Cook, David M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dopamine agonists; Prolactinomas

Indexed keywords

4 AMINOBUTYRIC ACID; AMOXAPINE; BETA ENDORPHIN; BROMOCRIPTINE; CABERGOLINE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENKEPHALIN; ESTROGEN; FLUOXETINE; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLDOPA; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; OPIATE; OPIATE AGONIST; ORAL CONTRACEPTIVE AGENT; PERGOLIDE; PHENOTHIAZINE DERIVATIVE; PROGESTERONE; PROLACTIN; PROTIRELIN; QUINAGOLIDE; RESERPINE; SULPIRIDE; THYROID HORMONE; UNINDEXED DRUG; VERAPAMIL;

CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GROWTH HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOPHYSIS; LACTATION; NEUROENDOCRINE SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PROLACTIN RELEASE; PROLACTINOMA; REVIEW; SIDE EFFECT; TUMOR GROWTH;

AMENORRHEA; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; ESTROGENS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; PITUITARY NEOPLASMS; PREGNANCY; PROLACTIN; PROLACTINOMA;

EID: 17644388073     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-005-5220-4     Document Type: Review

References (31)

1. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, Martin PM, Jaquet P, Brue T. Macroprolactinemia revisted: A study on 106 patients. J Clin Endocrinol Metab 2002;87(2):581-588.
2. Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big prolatin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 2002;87(12):5410-5415.
3. Schlechte JA. The macroprolactin problem. J Clin Endocrinol Metab 2002;87(12):5408-5409.
4. Guay AT, Sabharwal P, Varma S, Malarkey WB. Delayed diagnosis of psychological erectile dysfunction because of the presence of macroporlactinemia. J Clin Endocrinol Metab 1996;81:2512-2514.
5. Leslie H, Courtney CH, Bell PM, Madden DR, McCance DR, Ellis PK, Sheridan B, Atkinson AB. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Metab 2001;86:2743-2746.
6. Vallette-Kasic S, Marange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, Martin PM, Jaquet P, Brue T. Macroprolactinemia Revisited: A study on 106 patients. J Clin Endocrinol Metab 2002;87(2):581-588.
7. Bevan JS, Burke CW, Esiri MM, Adams CBT. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med 1987;82:29-32.
8. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol 1996;44:305-309.
9. Barkan Al, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: The pitfall of the "high-dose hook effect": Case report. Neurosurgery 1998;42:913-915.
10. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: A prospective analysis. J Clin Endocrinol Metab 1989;68:412-418.
11. Von Werder K, Eversmann T, Fahlbusch R, et al. Development of hyperprolactinemia in patients with and with out prior operative treatment. Excerpta Med Int Congr Ser 1982;584:175-188.
12. March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML, Marrs RP, Mishell DR Jr. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1981;139:835-844.
13. Weiss MH, Teal J, Gott P, Wycoff R, Yadley R, Apuzzo ML, Giannotta SL, Kletzky O, March C. Natural history of microprolactinomas: Six-year follow-up. Neurosurgery 1983;12:180-183.
14. Koppelman MC, Jaffe MJ, Fieth KG, Caruso RC, Loriaux DL. Hyperprolactinemia, amenorrhea, and galactorrhea. Ann Intern Med 1984;100:115-121.
15. Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril 1987;48:67-71.
16. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol 1996;45:299-303.
17. Wingrave SJ, Kay CR, Vessey MP. Oral contraceptives and pituitary adenomas. BMJ 1980;1:685-686.
18. Corenbulum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993;59:671-673.
19. De Rosa M, Zarrilli S, Vitale G, Di Somma C, Orio F, Tauchmanova'L, Lombardi G, Colao A. Six months of treatment with cabergoline restores sexual potency in hyperprolacinemic males: An open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004;89(2):621-625.
20. Webster J, Piscitelli G, Plli A, Ferrari C, Ismail I, Scanlon M. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. 1994;331:904-909.
21. Verhelst J, Abs R, Maiter D, Van Den Bruel A, Vandeweghe M, Belkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84(7):2518.
22. Molitch ME. Prolactinomas. In: Melmed S, ed. The Pituitary. Cambridge, MA, Balckwell Science, Inc., 1995:443-477.
23. Freda PU, Andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs P, Wardlaw SL. Long-term treatment of Prolactin-Secreting Macroadenomas with Pergolide. J Clin Endocrinol Metab 2000;85(1):8.
24. Colao An, Bitale G, Cappabianca P, Briganti F, Ciccarelli A, DeRosa M, Zarrilli S, Lonbardi G. Outcome of Cabergoline treatment in men with Prolactinoma: Effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clinc Endocrinol Metab 2003;89(4):1704-1711.
25. Colao A, De Sarno A, Landi M, Scavuzzo F, Cappabianca P, Pivonello R, Annunziato G, Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naïve patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J Clinc Endocrinol Metab 2000;85(6):2247.
26. Colao A, De Sarno A, Landi M, Scavuzzo F, Cappabianca P, Pivonello R, Annunziato G, Lombardi G. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clinc Endocrinol Metab 1997;82(11):3574.
27. Biller B, Molitch M, Lee Vance M, Cannistraro K, Davis K, Simons J, Schoenfelder JR, Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clinc Endocrinol Metab 1996;81(6):2338.
28. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. New Eng J Med 2003;349:2023-2033.
29. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clinc Endocrinol Metab 1998;83(2):374.
30. Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Pertil Steril 1979;31:363-372.
31. Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985;312:1365-1370.